{"id":37077,"date":"2025-07-10T14:55:04","date_gmt":"2025-07-10T06:55:04","guid":{"rendered":"https:\/\/flcube.com\/?p=37077"},"modified":"2025-07-10T14:55:05","modified_gmt":"2025-07-10T06:55:05","slug":"novo-nordisk-invests-111-million-in-tianjin-quality-control-lab-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37077","title":{"rendered":"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion"},"content":{"rendered":"\n<p>Denmark-based pharmaceutical giant <strong>Novo Nordisk A\/S (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>)<\/strong> has signed a <strong>Memorandum of Understanding (MOU)<\/strong> with the <strong>Tianjin Economic-Technological Development Area (TEDA) Administrative Committee<\/strong>, committing <strong>RMB 800 million (USD 111 million)<\/strong> to expand the quality control laboratory at its Tianjin manufacturing site. This move underscores Novo Nordisk&#8217;s strategic focus on strengthening its global production capabilities while deepening its presence in China.<\/p>\n\n\n\n<p><strong>Company Overview<\/strong><br>Novo Nordisk, a leader in diabetes and obesity care, has consistently demonstrated its commitment to innovation and expansion. The Tianjin facility, a cornerstone of the company\u2019s manufacturing network, has been a recipient of continuous investment since its inception. This latest infusion of capital highlights Novo Nordisk&#8217;s dedication to enhancing its operational excellence and meeting the growing demand for high-quality pharmaceutical products.<\/p>\n\n\n\n<p><strong>Investment Details<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Investment<\/strong>: RMB 800 million allocated for the expansion of the quality control laboratory, ensuring adherence to global standards and regulatory requirements.<\/li>\n\n\n\n<li><strong>Previous Investments<\/strong>: In March 2024, Novo Nordisk initiated an RMB 4 billion (USD 557 million) expansion project focused on sterile drug production, significantly boosting its manufacturing capacity.<\/li>\n\n\n\n<li><strong>Cumulative Investment<\/strong>: With this latest funding, the company&#8217;s total investment in Tianjin surpasses <strong>RMB 10 billion (USD 1.4 billion)<\/strong>, reflecting its long-term commitment to the region.<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Significance<\/strong><br>The expansion of the quality control laboratory is a pivotal step in Novo Nordisk&#8217;s strategy to maintain its leadership in the global pharmaceutical market. By enhancing its quality assurance capabilities, the company aims to ensure the highest standards of safety and efficacy for its products. This investment also aligns with China&#8217;s growing emphasis on high-quality healthcare solutions.<\/p>\n\n\n\n<p><strong>Market Impact<\/strong><br>Novo Nordisk&#8217;s continued investment in Tianjin not only solidifies its position as a key player in the global pharmaceutical industry but also underscores the strategic importance of China in its growth strategy. The expansion is expected to drive operational efficiency, support product innovation, and meet the increasing demand for diabetes and obesity treatments worldwide.<\/p>\n\n\n\n<p><strong>Conclusion<\/strong><br>With this RMB 800 million investment and the initiation of its Series C2 funding, Novo Nordisk is poised to further its mission of delivering transformative diagnostic solutions for women worldwide. The company\u2019s commitment to innovation, global expansion, and addressing critical healthcare needs positions it as a key player in the rapidly evolving IVD landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Denmark-based pharmaceutical giant Novo Nordisk A\/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[148,860],"class_list":["post-37077","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Denmark-based pharmaceutical giant Novo Nordisk A\/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU) with the Tianjin Economic-Technological Development Area (TEDA) Administrative Committee, committing RMB 800 million (USD 111 million) to expand the quality control laboratory at its Tianjin manufacturing site. This move underscores Novo Nordisk&#039;s strategic focus on strengthening its global production capabilities while deepening its presence in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37077\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion\" \/>\n<meta property=\"og:description\" content=\"Denmark-based pharmaceutical giant Novo Nordisk A\/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU) with the Tianjin Economic-Technological Development Area (TEDA) Administrative Committee, committing RMB 800 million (USD 111 million) to expand the quality control laboratory at its Tianjin manufacturing site. This move underscores Novo Nordisk&#039;s strategic focus on strengthening its global production capabilities while deepening its presence in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37077\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T06:55:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-10T06:55:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1006.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion\",\"datePublished\":\"2025-07-10T06:55:04+00:00\",\"dateModified\":\"2025-07-10T06:55:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077\"},\"wordCount\":385,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1006.webp\",\"keywords\":[\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37077#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37077\",\"name\":\"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1006.webp\",\"datePublished\":\"2025-07-10T06:55:04+00:00\",\"dateModified\":\"2025-07-10T06:55:05+00:00\",\"description\":\"Denmark-based pharmaceutical giant Novo Nordisk A\\\/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU) with the Tianjin Economic-Technological Development Area (TEDA) Administrative Committee, committing RMB 800 million (USD 111 million) to expand the quality control laboratory at its Tianjin manufacturing site. This move underscores Novo Nordisk's strategic focus on strengthening its global production capabilities while deepening its presence in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37077\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1006.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1006.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37077#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Denmark-based pharmaceutical giant Novo Nordisk A\/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU) with the Tianjin Economic-Technological Development Area (TEDA) Administrative Committee, committing RMB 800 million (USD 111 million) to expand the quality control laboratory at its Tianjin manufacturing site. This move underscores Novo Nordisk's strategic focus on strengthening its global production capabilities while deepening its presence in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37077","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion","og_description":"Denmark-based pharmaceutical giant Novo Nordisk A\/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU) with the Tianjin Economic-Technological Development Area (TEDA) Administrative Committee, committing RMB 800 million (USD 111 million) to expand the quality control laboratory at its Tianjin manufacturing site. This move underscores Novo Nordisk's strategic focus on strengthening its global production capabilities while deepening its presence in China.","og_url":"https:\/\/flcube.com\/?p=37077","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-10T06:55:04+00:00","article_modified_time":"2025-07-10T06:55:05+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1006.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37077#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37077"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion","datePublished":"2025-07-10T06:55:04+00:00","dateModified":"2025-07-10T06:55:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37077"},"wordCount":385,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37077#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1006.webp","keywords":["Novo Nordisk","NYSE: NVO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37077#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37077","url":"https:\/\/flcube.com\/?p=37077","name":"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37077#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37077#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1006.webp","datePublished":"2025-07-10T06:55:04+00:00","dateModified":"2025-07-10T06:55:05+00:00","description":"Denmark-based pharmaceutical giant Novo Nordisk A\/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU) with the Tianjin Economic-Technological Development Area (TEDA) Administrative Committee, committing RMB 800 million (USD 111 million) to expand the quality control laboratory at its Tianjin manufacturing site. This move underscores Novo Nordisk's strategic focus on strengthening its global production capabilities while deepening its presence in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37077#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37077"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37077#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1006.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1006.webp","width":1080,"height":608,"caption":"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37077#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1006.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37077"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37077\/revisions"}],"predecessor-version":[{"id":37079,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37077\/revisions\/37079"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37078"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}